Schizophrenia & Psychotic Disorders

As many as one-quarter of suicide attempts are associated with psychotic experiences, according to a systematic review and meta-analysis published online in JAMA Psychiatry.


Schizophrenia is a neurodevelopmental, rather than a neurodegenerative disorder, meaning cognitive control deficits are present at onset and not the result of brain deterioration, a new study suggests.

MRI-based predictive tools could inform therapeutic decision making, potentially preventing functional impairment in patients at high clinical risk of psychosis and those with recent-onset depression, researchers say.

Intra-Cellular Therapies, Inc. has submitted a New Drug Application to the US Food and Drug Administration for lumateperone, a investigational medicine with a novel mechanism of action for the treatment of schizophrenia.

Rakesh Jain, MD, MPH

Are medications for tardive dyskinesia effective in mild, moderate, or severe cases? Get the answer from Psych Congress cochair Rakesh Jain, MD, MPH.

The primary outcome measure, time to first development of psychosis from randomization, did not differ significantly between the donepezil and placebo groups.




"Does schizophrenia cause inflammatory changes in the brain?"


“Is it true that schizophrenia and major depressive disorder have shared genetic underpinning?"



Christoph Correll, MD; Steven Potkin, MD; Suresh Durgam, MD; Cheng-Tao Chang, PhD; Balázs Szatmári, MD; István Laszlovszky, PharmD, PhD; Willie Earley, MD; Severus Tomescu, MD, MHA
Stanley Caroff, MD; Fan Mu, PhD; Rajeev Ayyagari, PhD; Traci Schilling, MD; Victor Abler, DO; Benjamin Carroll, PharmD
Benjamin Carroll, PharmD; Paul Juneau, MS; Debra Irwin, MD, MSPH
Gordon Loewen, PhD; Rosa Luo, EM; Evan Smith, BS; Grace Liang, PhD; Khodayar Farahmand, PharmD; Haig Bozigian, PhD; Christopher OкBrien, MD
Hubert Fernandez, MD; Mat Davis, PhD; Stewart Factor, DO; Robert Hauser, MD, MBA; Lars Jarskog, MD; Joohi Jimenez-Shahed, MD; Rajeev Kumar, MD, FRCPC; Stanislaw Ochudlo, MD, PhD; William Ondo, MD; Karen Anderson, MD



Psych Congress steering committee member Rakesh Jain, MD, MPH, discussed how to talk to patients with schizophrenia about using long-acting injectable treatments, as part of a presentation at the Psych Congress 1-Day Regional Meeting in Milwaukee. 

Psych Congress steering committee member Rakesh Jain, MD, MPH, discussed the advantages of treating patients with schizophrenia with long-acting injectable treatments, as part of a presentation at the Psych Congress 1-Day Regional Meeting in Milwaukee.

Joseph P. McEvoy, MD, discusses the reasons why specialized treatment programs are important after a first episode of psychosis